OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
ADVE56

Adventa Bhd

Medical Equipment, Supplies & DistributionVerified

Adventa Bhd maintains a strong liquidity position, with a current ratio of 5.6, indicating that it holds significantly more current assets than current liabilities. However, the company reported negative operating cash flow of MYR -6,198,000 and free cash flow of MYR -4,676,000, suggesting that it is currently spending more cash than it is generating from operations. The company's capital expenditure of MYR -5,300,000 reflects ongoing investment in long-term assets, but this is being funded by negative cash flows, which could raise concerns about long-term sustainability. Profitability metrics for Adventa Bhd are modest, with a return on equity (ROE) of 0.33% and a return on assets (ROA) of 0.30%. These figures are below the typical thresholds for strong performance in the medical equipment and supplies industry, where higher returns are often expected due to the capital-intensive nature of the business. The company's operating income of MYR 498,000 and net income of MYR 304,000 suggest limited profitability, which may constrain its ability to reinvest in growth or reward shareholders. The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. This lack of diversification could expose Adventa Bhd to higher operational risk if demand for medical equipment and supplies fluctuates. Geographically, the company operates primarily in Malaysia, as indicated by the MYR-based financials, and there is no evidence of significant international exposure. Looking ahead, Adventa Bhd's growth trajectory appears uncertain. The company's revenue of MYR 13,503,000 is relatively flat compared to historical data, and there is no indication of a clear upward trend. The negative operating and free cash flows suggest that the company may need to rely on external financing or asset sales to fund its operations and capital expenditures, which could impact its long-term growth potential. The risk assessment for Adventa Bhd highlights a medium liquidity risk, primarily due to the company's negative net cash position after accounting for total debt. While the company's debt-to-equity ratio is low at 0.01, indicating minimal leverage, the negative cash flows and capital expenditures raise concerns about its ability to maintain liquidity without external financing. The risk of dilution is currently low, as there is no evidence of recent share issuance or plans for future dilution. No recent filings or transcripts are available in the provided data to indicate any material events or strategic shifts at Adventa Bhd. The company's financial performance and risk profile remain largely unchanged from the latest available data.

30-day price · ADVE-0.01 (-6.3%)
Low$0.13High$0.18Close$0.15As of17 May, 00:00 UTC
Profile
CompanyAdventa Bhd
TickerADVE.KL
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryMedical Equipment, Supplies & Distribution
AI analysis

Business. Adventa Bhd provides medical equipment, supplies, and distribution services within the healthcare sector, generating revenue primarily through the sale and distribution of medical products.

Classification. Adventa Bhd is classified under the industry "Medical Equipment, Supplies & Distribution" within the Healthcare Services & Equipment business sector, with a confidence level of 0.92.

Adventa Bhd maintains a strong liquidity position, with a current ratio of 5.6, indicating that it holds significantly more current assets than current liabilities. However, the company reported negative operating cash flow of MYR -6,198,000 and free cash flow of MYR -4,676,000, suggesting that it is currently spending more cash than it is generating from operations. The company's capital expenditure of MYR -5,300,000 reflects ongoing investment in long-term assets, but this is being funded by negative cash flows, which could raise concerns about long-term sustainability. Profitability metrics for Adventa Bhd are modest, with a return on equity (ROE) of 0.33% and a return on assets (ROA) of 0.30%. These figures are below the typical thresholds for strong performance in the medical equipment and supplies industry, where higher returns are often expected due to the capital-intensive nature of the business. The company's operating income of MYR 498,000 and net income of MYR 304,000 suggest limited profitability, which may constrain its ability to reinvest in growth or reward shareholders. The company's revenue is concentrated in a single business segment, as no segmental breakdown is provided in the available data. This lack of diversification could expose Adventa Bhd to higher operational risk if demand for medical equipment and supplies fluctuates. Geographically, the company operates primarily in Malaysia, as indicated by the MYR-based financials, and there is no evidence of significant international exposure. Looking ahead, Adventa Bhd's growth trajectory appears uncertain. The company's revenue of MYR 13,503,000 is relatively flat compared to historical data, and there is no indication of a clear upward trend. The negative operating and free cash flows suggest that the company may need to rely on external financing or asset sales to fund its operations and capital expenditures, which could impact its long-term growth potential. The risk assessment for Adventa Bhd highlights a medium liquidity risk, primarily due to the company's negative net cash position after accounting for total debt. While the company's debt-to-equity ratio is low at 0.01, indicating minimal leverage, the negative cash flows and capital expenditures raise concerns about its ability to maintain liquidity without external financing. The risk of dilution is currently low, as there is no evidence of recent share issuance or plans for future dilution. No recent filings or transcripts are available in the provided data to indicate any material events or strategic shifts at Adventa Bhd. The company's financial performance and risk profile remain largely unchanged from the latest available data.
Key takeaways
  • Adventa Bhd has a strong current ratio of 5.6, but negative operating and free cash flows raise concerns about liquidity sustainability.
  • The company's ROE and ROA are below typical industry benchmarks, indicating limited profitability.
  • Revenue is concentrated in a single business segment and geographic market, increasing operational risk.
  • Growth appears to be constrained by flat revenue and negative cash flows, with no clear upward trajectory.
  • Liquidity risk is moderate, and dilution risk is currently low.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyMYR
Revenue$13.5M
Gross profit
Operating income$498.0k
Net income$304.0k
R&D
SG&A
D&A
SBC
Operating cash flow-$6.2M
CapEx-$5.3M
Free cash flow-$4.7M
Total assets$102.3M
Total liabilities$9.7M
Total equity$92.5M
Cash & equivalents
Long-term debt$789.0k
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$97.6M$8.0M$13.1M$8.6M
FY-3$59.0M-$4.6M-$5.1M-$4.4M
FY-2$37.3M-$9.6M-$9.1M-$26.4M
FY-1$58.3M$4.1M$2.2M-$22.4M
FY0$53.3M-$3.3M-$5.5M-$4.4M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$98.7M$68.3M
FY-3$74.4M$63.0M
FY-2$104.4M$91.9M
FY-1$112.4M$98.0M
FY0$108.0M$87.4M
PeriodOCFCapExFCFSBC
FY-4-$15.0M-$593.7k$8.6M
FY-3$322.8k-$248.7k-$4.4M
FY-2-$2.7M-$17.9M-$26.4M
FY-1-$8.5M-$25.0M-$22.4M
FY0$49.0k-$4.4M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7$13.5M$498.0k$304.0k-$4.7M
FQ-6$12.3M$391.0k$342.0k-$13.3M
FQ-5$15.4M$1.3M$663.0k-$3.0M
FQ-4$17.0M$1.4M$881.1k-$750.2k
FQ-3$13.6M$389.0k$313.0k-$6.0M
FQ-2$13.9M$601.0k$438.0k$455.0k
FQ-1$11.8M$312.0k$172.0k$410.0k
FQ0$14.0M-$4.6M-$6.4M-$6.2M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7$102.3M$92.5M
FQ-6$109.5M$93.7M
FQ-5$114.2M$94.2M
FQ-4$112.4M$98.0M
FQ-3$116.8M$97.4M
FQ-2$117.1M$97.4M
FQ-1$107.1M$93.8M
FQ0$108.0M$87.4M
PeriodOCFCapExFCFSBC
FQ-7-$6.2M-$5.3M-$4.7M
FQ-6$2.5M-$19.1M-$13.3M
FQ-5-$7.2M-$23.0M-$3.0M
FQ-4-$8.5M-$25.0M-$750.2k
FQ-3$4.0M-$6.6M-$6.0M
FQ-2$3.4M-$6.9M$455.0k
FQ-1-$272.0k$410.0k
FQ0$49.0k-$6.2M
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$92.5M
Net cash-$789.0k
Current ratio5.6
Debt/Equity0.0
ROA0.3%
ROE0.3%
Cash conversion-20.4%
CapEx/Revenue-39.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskMedium
  • Net cash is negative after subtracting total debt.
Industry benchmarks
Activity: Healthcare Services & Equipment · cohort 369 companies
MetricADVEActivity
Op margin3.7%3.9% medp25 -31.3% · p75 14.4%below median
Net margin2.3%2.4% medp25 -30.5% · p75 11.1%below median
Gross margin46.7% medp25 28.2% · p75 63.1%
R&D / revenue6.9% medp25 6.7% · p75 7.1%
CapEx / revenue-39.2%-4.8% medp25 -11.6% · p75 -2.4%bottom quartile
Debt / equity1.0%17.9% medp25 2.7% · p75 52.2%bottom quartile
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-05 00:55 UTC#379d4895
Source: analysis-pipeline (hybrid)Generated: 2026-05-27 06:43 UTCJob: 09da7632